Investigation of Carbohydrates and Their Derivatives as Crystallization Modifiers by Dohnal, Jiří & Jampílek, Josef
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5 
 
 
 
 
© 2012 Jampílek and Dohnal, licensee InTech. This is an open access chapter distributed under the terms of 
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Investigation of Carbohydrates and Their 
Derivatives as Crystallization Modifiers 
Josef Jampílek and Jiří Dohnal 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/50626 
1. Introduction 
Development in the field of pharmaceutical administration has resulted in the discovery of 
highly sophisticated drug delivery systems that allow for the maintenance of a constant 
drug level in an organism. Contrary to these revolution biopharmaceutical results, over the 
last ten years, the number of poorly soluble drugs has steadily increased. Estimates state 
that 40% of the drugs in the pipelines have solubility problems. Progress in high throughput 
screening methods leads to an even greater amount of newly discovered drugs, but a lot of 
them have poor water solubility. Literature states that about 60% of all drugs coming 
directly from synthesis are nowadays poorly soluble. Meanwhile the five key physico-
chemical properties, such as pKa, solubility, permeability, stability and lipophilicity, in early 
compound screening should be optimized. Compounds with insufficient solubility carry a 
higher risk of failure during discovery and development, since insufficient solubility may 
compromise other property assays, mask additional undesirable properties, influence both 
pharmacokinetic and pharmacodynamic properties of the compound and finally may affect 
the developability of the compound. Poor solubility in water correlates with poor 
bioavailability. If there is no way to improve drug solubility, it will not be able to be 
absorbed from the gastrointestinal tract into the bloodstream and reach the site of action 
(Junghanns & Müller, 2008; Payghan et al., 2008). 
Modification/optimization of unfavourable physico-chemical properties of these drugs is 
possible through increasing their water solubility or improving permeability. There are 
many ways to solubilize certain poorly soluble drugs. But these methods are limited to 
drugs with certain properties in regard to their chemistry or, for example, to their molecular 
size or conformation. 
Aqueous solubility can be increased by chemical exchange: (i) salts, co-crystals or solvates 
formation (affects also chemical stability, polymorphism, technological workability); 
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(ii) substitution by hydrophilic groups (effect of drugs with small molecules can be 
decreased); (iii) prodrug preparation (hydrolyzable amides or semiesters with polybasic 
acids). In general, the following structural modifications are the best way to improve 
permeability: (i) replacement of ionisable groups by non-ionizable groups; (ii) increase of 
lipophilicity; (iii) isosteric replacement of polar groups; (iv) esterification of carboxylic acid; 
(v) reduction of hydrogen bonding and polarity; (vi) reduction of size; (vii) addition of a 
non-polar side chain; (viii) preparation of prodrugs. Generally, these strategies are based on 
a few fundamental concepts: change of ionizability, lipophilicity, polarity or change of 
hydrogen bond donors or acceptors. Both approaches interact logically. 
Based on these facts, pre-formulation/formulation can be another and mostly successful 
strategy for improving aqueous solubility and/or permeability and subsequently 
bioavailability. For example, selection of a suitable salt, particle size reduction (till nano size) 
connected with an increase of the surface area, change of polymorphic forms, selection of 
appropriate excipients to function as solubilizers/transporters (surfactants or pharmaceutical 
complexing agents, permeability enhancers) can be used for the oral dosage form (Kerns & 
Di, 2008). 
It is well-known that crystalline materials obtain their fundamental physical properties from 
the molecular arrangement within the solid, and altering the placement and/or interactions 
between these molecules can, and usually does, have a direct impact on the properties of the 
particular solid. Currently, solid-state chemists call upon a variety of different strategies 
when attempting to alter the chemical and physical solid-state properties of active 
pharmaceutical ingredients (APIs), namely, the formation of salts, polymorphs, hydrates, 
solvates and co-crystals (Seddon & Zaworotko, 1999; Datta & Grant, 2004; Grepioni & Braga, 
2007; Schultheiss & Newman, 2009). 
Currently, salt formation is one of the primary solid-state approaches used to modify the 
physical properties of APIs, and it is estimated that over half of the medicines on the market 
are administered as salts (Bighley et al., 1996; Stahl & Wermuth, 2002; Gu & Grant, 2003.). 
However, a major limitation within this approach is that the API must possess a suitable 
(basic or acidic) ionizable site. In comparison, co-crystals (multi-component assemblies held 
together by freely reversible, non-covalent interactions) offer a different pathway, where any 
API regardless of acidic, basic or ionizable groups, could potentially be co-crystallized. This 
aspect helps to complement existing methods by reintroducing molecules that had limited 
pharmaceutical profiles based on their non-ionizable functional groups. Since the primary 
structure of a drug molecule does not change in co-crystals, their development in terms of 
the regulation "New Chemical Entities (NCEs)" of the U.S. Food and Drug Administration 
(FDA) as well as European Commission Regulation (EC) No. 258/97 carries fewer risks and 
takes much less time; nevertheless stability and bioequivalent studies are still necessary. In 
addition, the number of potential non-toxic co-crystal formers (or co-formers) that can be 
incorporated into a co-crystalline reaction is numerous, e.i. pharmaceutical excipients, amino 
acids, food additives, nutraceuticals, see for example the GRAS list (Generally Regarded as 
Safe) or the EAFUS Database (Everything Added to Food in the United States), both 
published by the FDA. 
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It should be made clear that no one particular strategy offers a solution for property 
enhancement of all APIs. Each API must be examined and evaluated on a case-by-case basis 
in terms of molecular structure and desired final properties (Schultheiss & Newman, 2009). 
2. Polymorphism 
The term "polymorphism" (from Greek: polys = many, morfé = form) was first used by 
Mitscherlich in 1822. He noticed that one compound of a certain chemical composition can 
crystallize into several crystal forms (Mitscherlich, 1822). Polymorphism is an ability of 
substances to exist in two or more crystal modifications differing from each other by 
structure and/or molecule conformation in the crystal lattice. The concept of polymorphism 
is often confounded with isomorphism or pseudopolymorphism. These concepts are 
interconnected but there are great differences between them. 
In contrast to polymorphism when one substance able to form different crystal modifications 
is considered, in case of isomorphism two or more different substances that have just similar 
structure but form the same crystal modifications are considered. Such substances can even 
form so-called isomorphous series. Most often they originate as a result of co-crystallization 
of isomorphous substances from the mixture of their saturated solutions. A typical example is 
sulphates: magnesium sulphate, zinc sulphate and nickel sulphate crystallizing as 
heptahydrates. Also pseudopolymorphism should be distinguished from polymorphism. The 
concept of pseudopolymorphism is used for crystalline forms which also comprise solvent 
molecules as an integral part of their structure. These pseudopolymorphs are sometimes 
called solvates or hydrates if the solvent is water (Rodríguez-Spong et al., 2004). 
The fundamental forms of solid substances can be classified into polymorphs, 
solvates/desolvated solvates and amorphous substances. A co-crystal can be defined as a 
multiple-component crystal, in which two or more molecules that are solid under ambient 
conditions coexist through a hydrogen bond (see Fig. 1 and Fig. 2). Polymorphism can be  
  
Figure 1. API solid form classification based on structure and composition. (Ref. Sekhon, 2009) (Taken 
and adapted with the permission of the author.) 
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single-component crystals multiple-component crystals
solvates 
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classified depending on the fact if the molecule occurs in different conformations or is the 
same. If the molecule can have different conformations that crystallize differently and so the 
molecule is flexible, conformation polymorphism is observed. If the molecule is rigid, does 
not have any conformations and polymorphs differ only by their packing in the crystalline 
structure, this is the case of package polymorphism (Sharma et al., 2011). 
Polymorphism should be distinguished from crystal morphology that represents 
crystallization of a substance from different solvents with a change of the form but without 
modification of the crystalline structure. 
 
Figure 2. Schematic illustration of polymorphism of solid compounds. (Ref. Kratochvíl, 2009) (Taken 
and adapted from the presentation "Pharmaceutical Co-crystals" with the permission of the author.) 
In the pharmaceutical practice it is conventional to collectively call all polymorphs, solvates 
and polyamorphs of the same API as solid forms or polymorphs in the extended meaning 
and designate them by, for example, Roman numerals or letters. It should be taken into 
consideration that designation of polymorphs is often non-uniform; it originates 
historically; therefore it is possible that two different polymorphs will be designated by 
different authors in the same way. A problem of pharmaceutical producers is polymorphic 
transitions in organic systems that are often hysteresis, badly defined and solvent-
mediated. Polymorphic transitions can occur at all technological stages of drug production 
(at final API crystallization, wet granulation, micronization, tabletting or in ready tablets, 
for example, under the influence of auxiliaries – excipients). At drug registration, national 
regulation authorities demand description of all solid forms and possible phase transitions 
of the drug as well as a prescribed guarantee of the product polymorphic purity from 
pharmaceutical companies. At present approximately 85% of pharmaceutical products are 
solid formulations; therefore no manufacturer can afford to ignore the issue of 
polymorphism. 
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2.1. Crystallization 
During crystallization a self-assembly supramolecular process takes place when randomly 
oriented molecules assemble into internally structured crystals (Kratochvíl, 2007). There are 
several ways of crystallization: (i) by evaporation of solvent; (ii) by addition of antisolvent 
(product precipitation); (iii) by cooling of solution; (iv) by change of pH ; (v) by addition of a 
compound that will produce the desired product by a chemical reaction; (vi) by 
lyophilisation, sublimation or cooling of melt (Kratochvíl, 2010). The first two possibilities 
were used in the experimental part. 
The process of crystal formation is a complicated kinetic process which, if we simplify, is 
composed of nucleation, subsequent crystal growth around the formed crystal nuclei and 
growth termination. This happens at precipitation of a solid substance in the crystalline 
form from solution or at solidification of a substance.  
The basis of nucleation is the quickest formation of the crystal nucleus. By constant sequence 
of molecules addition molecular aggregates, clusters, originate. The aggregates spontaneously 
impact and thus disintegrate but also grow. When they achieve the critical size, they become 
nuclei that do not disintegrate spontaneously but, to the contrary, only grow into a crystal. 
Nuclei can be classified into primary and secondary. Primary nucleation is further divided into 
homogenous and heterogeneous. Homogenous nucleation is characterized by formation of 
nuclei as a result of random impacts of aggregates somewhere in the solution volume without 
the presence of any foreign matter. By contrast, heterogeneous nucleation is assisted by foreign 
matters, for example, a stirrer. Secondary nucleation is also called seeded nucleation – small 
crystals (nuclei, seeds) of a desired crystal are added to the original solution. Seeding is 
successfully applied for systems where polymorphous behaviour cannot be excluded. Seeding 
of the system with a desired polymorph assures that an undesired polymorph will not be 
formed. After formation of the nucleus the system pass to the second mentioned crystallization 
phase. In this phase growth of crystals from the formed nucleus continues. If an API is 
crystallized with a co-crystallization partner, for example excipient or another API, with co-
crystals formation, such process is called co-crystallization. 
2.2. Properties of solid forms 
For polymorphic drugs, the most thermodynamically stable polymorph is usually preferred. 
This polymorph normally assures reproducible bioavailability for the whole period of the 
pharmaceutical shelf life under different storing conditions that are possible in practice. A 
significant advantage is that production of such a polymorph is mostly easier controlled on 
an industrial scale. But in some cases a metastable crystalline form or an amorphous form is 
preferred due to patent and medical reasons. This happens when a higher concentration of 
an API in the system or faster dissolution of poorly soluble substances is required. Certain 
substances are used in the amorphous form also due to the fact that a crystalline form of the 
compound was not obtained. When an amorphous form or a metastable crystalline 
polymorph is used, especial attention is to be paid to safety assurance and the effectiveness 
of the drug for the whole shelf life period. These aspects are to be assured also for storing 
conditions in other climatic zones. 
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Though the biological effect of an API is induced by interaction of the drug molecule with a 
target receptor when cell natural chemistry is influenced primarily by conformation 
changes, it is important in what solid phase the drug is administered to the patient. That 
means that not only the molecular but also the crystalline structure of an API is essential. 
The crystalline structure influences not only chemical and physical stability but also the 
drug dissolution rate and so can affect markedly the drug bioavailability. On the other hand, 
an amorphous form may have a considerably higher dissolution rate than the most stable 
polymorph. Great differences in the solubility and the dissolution rate of polymorphs can be 
a reason of significant differences in their distribution in the organism. Low plasma 
concentration can theoretically cause incomplete occupation of respective membrane 
receptors at the site of action (they are blocked by a substrate), or biological activity can 
change from agonist to antagonist or vice versa. 
However, the dissolution rate is not the only important parameter of the difference between 
polymorphs. There can be also differences in crystal size and shape that influence milling, 
tabletting, filtration, looseness and other important technological parameters. There are also 
differences in chemical reactivity, thermal stability, hygroscopicity, density, hardness, etc. 
Thus it can be stated that different arrangement and conformation change of molecules in 
the crystal structure lead to differences in properties as follows: (i) mechanical (hardness, 
compactness, etc.); (ii) surface (surface energy, interfacial tension, etc.); (iii) kinetic 
(dissolution values, stability, etc.); (iv) spectroscopic (electronic, vibrational state transition, 
etc.); (v) thermodynamic (melting point, sublimation, enthalpy, entropy, etc.); (vi) packing 
properties (molar volume a density, hygroscopicity, etc.) (Brittain, 2009). 
2.3. Multi-component solids 
Usually solid crystal substances can exist as mono-component or multi-component. Mono-
component systems contain, as evident from the name, only one component, and multi-
component systems consist of two or more components. In pharmaceutics this is a crystal 
composed of an API and an additional molecule that determines the type of the multi-
component system, pseudopolymorph. As illustrated in Fig. 1, the additional molecule of 
hydrates is water; of solvates, a solvent; of salts, an ionizable component; and of co-crystals, 
a co-crystallization partner (Stahly, 2007; Kratochvíl, 2010). All these systems can be 
polymorphic (see Fig. 1 and Fig. 2). Due to the breadth of the topic and the focus of this 
paper on preparation of co-crystals, only co-crystals will be described in more details. 
3. Co-crystals 
The term "co-crystal" (also written as cocrystal) originates from "a composite crystal" 
(Desiraju, 2003). The term and the definition of co-crystal is a subject of topical debate. In 
principle this is a multi-component system of host and guest type; both components are 
solid in pure state and under ambient conditions. There are a lot of definitions; for example, 
Stahly defines co-crystals as molecular complexes that contain two or more different 
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molecules in the same crystal structure (Stahly, 2007). Bhogala and Nangia define co-crystals 
as multi-component solid-state assemblies of two or more compounds held together by any 
type or combination of intermolecular interactions (Bhogala & Nangia, 2008). Childs and 
Hardcastle define co-crystals as a crystalline material made up of two or more components, 
usually in a stoichiometric ratio, each component being an atom, ionic compound, or 
molecule (Childs & Hardcastle, 2007). The simplest definition of co-crystals was proposed 
by Bond: "synonym for multi-component molecular crystal" (Bond, 2007). Also the 
definition of Aakeröy and Salmon can be recognized. They describe co-crystal as 
stoichiometric structurally homogeneous multi-component crystalline material of host-guest 
type that contains two or more neutral building blocks (discrete neutral molecular species 
that are solids at ambient conditions) that are present in definite amounts whereas all solids 
containing ions, including complex transition-metal ions, are excluded) (Aakeröy & Salmon, 
2005). Jones defines co-crystal as a crystalline complex of two or more neutral molecular 
constituents bound together in the crystal structure through non-covalent interactions, often 
including hydrogen bonding (Jones et al., 2006) and Zaworotko says that co-crystals are 
formed between a molecular or ionic API and a co-crystal former that is a solid under 
ambient conditions (Vishweshwar et al., 2006a). 
The host is an API, and the guest is a co-crystallization partner (an excipient or another API). 
Note that according to the definition by Aakeröy and Salmon co-crystals are different from 
solvates by the fact that the host and the guest of co-crystals are in the solid phase, while 
solvates contain both a solid phase and a solvent (or its residual), i.e. a liquid phase. 
However, there is still the problem of a boundary between the salt and the co-crystal, 
because according to the last mentioned definition of Aakeröy and Salmon, ions as 
co-crystal components are excluded, so on Fig. 3 only the first example of two is a co-crystal 
according to the mentioned definition. The borderline between salts and co-crystals is 
blurred and can be distinguished by the location of the proton between an acid and a base. 
This state can be denoted as salt–co-crystal continuum (Childs et al., 2007). 
Several types of co-crystals can be distinguished: (i) "simple" co-crystals; (ii) solvated 
(hydrated) co-crystals – the co-crystal contains a component that is liquid at ambient 
temperature; (iii) salt co-crystals – the host is an ionized form; (iv) solvated salt co-crystals; 
(v) polymorphs of all previous types of co-crystals. 
3.1. Properties of co-crystals 
Pharmaceutical co-crystals, that is, co-crystals that are formed between an API and 
pharmaceutically acceptable (GRAS) compounds (co-crystal formers, counterions) that are 
solid under ambient conditions, represent a new paradigm in API formulation that might 
address important intellectual and physical property issues in the context of drug 
development and delivery. 
Co-crystals can be understood as "addition compounds" or "organic molecular compounds". 
They are attractive to the pharmaceutical industry, because they offer opportunities to modify 
the chemical and/or physical properties of an API without the need to make or break covalent 
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bonds (see Fig. 4). The term "non-covalent derivatization" was coined for this approach. Co-
crystals of an API with excipients become very important as a tool to tune solubility and 
absorption. The application of co-crystal technologies has only recently been recognised as a 
way to enhance solubility, stability and the intellectual property position with respect to 
development of APIs (Vishweshwar et al., 2006b; Sekhon, 2009; Schultheiss & Newman, 2009). 
Co-crystallization with pharmaceutical excipients does not affect pharmacological activity of 
an API but can improve physical properties, such as solubility, hygroscopicity and 
compaction behaviour (Aakeröy et al., 2007; Rodríguez-Hornedo et al., 2007; Trask, 2007; Sun 
& Hou, 2008; Zaworotko, 2008). Co-crystals with the same active pharmaceutical ingredient 
will have strikingly different pharmaceutical properties (melting point, solubility, 
dissolution, bioavailability, moisture uptake, chemical stability, etc.), depending on the 
nature of the second component. Some of co-crystals formed had higher and some lower 
melting points as compared to their pure components, for example, succinic acid (Mp=135.3), 
urea (Mp=188.9), co-crystal of succinic acid-urea (Mp=149.9) (Walsh et al., 2003). 
  
Figure 3. Possible multi-component systems: co-crystals, salt co-crystals and derived multi-component 
solids. (Ref. Schultheiss & Newman, 2009; reprinted and adapted with permission from Schultheiss N., 
Newman A. Pharmaceutical co-crystals and their physicochemical properties. Crystal Growth & Design 
2009, 9(6): 2950–2967. Copyright 2009 American Chemical Society.)  
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Figure 4. Frequency of occurrence of organic molecular co-crystals in the Cambridge Structural 
Database from 1988 to 2007. For the purposes of this graph, co-crystals are distinct from solvates, 
hydrates and simple salts. (Ref. Childs & Zaworotko, 2009; reprinted with permission from Childs S.L., 
Zaworotko M.J. The reemergence of cocrystals: The crystal clear writing is on the wall introduction to 
virtual special issue on pharmaceutical cocrystals. Crystal Growth&Design 2009, 9(10): 4208-4211. 
Copyright 2009 American Chemical Society.)  
Scientists showed that modifying the physical properties of a pharmaceutical compound 
through pharmaceutical co-crystal formation improved the performance of a drug known to 
have poor solubility (Vishweshwar et al., 2006a). Pharmaceutical co-crystallization is a 
reliable method to modify physical and technical properties of drugs such as solubility 
increase/decrease, change of dissolution rate, stability, hygroscopicity and compressibility 
without alternating their pharmacological behaviour (Ranganathan, 1999; Fleischman et al., 
2003; Almarsson & Zaworotko, 2004; Childs et al., 2004; Peterson et al.; 2006; Hickey et al., 
2007; Žegarać et al., 2007; Schultheiss & Newman, 2009). 
The use of co-crystals in drug design and delivery and as functional materials with potential 
applications as pharmaceuticals has recently attracted considerable interest (Fleischman et 
al., 2003; Jones et al., 2006; McNamara et al., 2006; Peterson et al., 2006; Vishweshwar et al., 
2006a). Pharmaceutical co-crystals have been described for many drugs such as 
acetaminophen, aspirin, ibuprofen, flurbiprofen, sulfadimidine, etc. (Vishweshwar et al., 
2005; Vishweshwar et al., 2006b; Caira, 2007; Rodríguez-Hornedo et al., 2007; Babu et al., 
2008; Sarma et al., 2008,). Co-crystals of antitubercular drugs with dicarboxylic acids were 
reported using carboxylic acid-pyridine synthon as a reliable tool (Vishweshwar et al., 2003). 
The co-crystal of piracetam-L-tartaric acid showed improved hygroscopic properties 
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(Viertelhaus et al., 2009). Co-crystal forming abilities of two anti-HIV drugs (lamivudine and 
zidovudine) were studied to investigate the general applicability (Bhatt et al., 2009). Trimer 
co-crystals of cis-itraconazole-succinic acid were prepared and characterized by the 
possibility of achieving the higher oral bioavailability normally observed for amorphous 
forms of water-insoluble drugs (Remenar et al., 2003). The novel pharmaceutical co-crystal 
norfloxacin saccharinate dihydrate and its co-crystal, norfloxacin saccharinate–saccharin 
dihydrate were reported (Velaga et al., 2008). 
3.2. Design of co-crystals 
Co-crystallization is a result of competing molecular associations between similar molecules, 
or homomers, and different molecules, or heteromers. Instead, both components (host and 
guest) utilise prominent intermolecular non-covalent interactions such as hydrogen 
bonding, van der Waals forces and π-π stacking interactions to combine and yield a uniform 
crystalline material. Hydrogen bonds are the basis of molecular recognition phenomena in 
pharmaceutical systems and are responsible for the generation of families of molecular 
networks with the same molecular components (single-component crystals and their 
polymorphs) or with different molecular components (multiple-component crystals or 
co-crystals) in the crystalline state (Jayasankar et al., 2006; Sekhon, 2009). The components in 
a co-crystal exist in simple definite stoichiometric ratios, e.g., 1:1, 1:2, 2:1, etc. Co-crystals 
have different crystal structures than the pure components, contain different intermolecular 
packing patterns and as such they often exhibit different physical properties than the pure 
components. Unlike salt formation, co-crystallisation does not rely on ionisation of the API 
and the counterion to make a solid. Co-crystals are an alternative to salts when these do not 
have the appropriate solid state properties or cannot be formed due to the absence of 
ionization sites in the API (Aakeröy & Salmon, 2005; Miroshnyk et al., 2009). 
The formation of a salt or a co-crystal can be predicted from pKa value of an acid (A) and a 
base (B). Salt formation generally requires a difference of about 3 pKa units between the 
conjugate base and the conjugate acid (A) i.e. [pKa (B) – pKa (A) ≥ 3] (Etter, 1990; Whitesides 
& Wong, 2006; Sekhon, 2009). In cases when ΔpKa = pKa (B) – pKa (A) = 0-3, the transfer of 
proton is ambiguous, and we can talk about the salt–co-crystal continuum (Childs et al., 
2007). 
Co-crystals can be prepared from two molecules of any shape or size having complementary 
hydrogen bond functionalities. The ability of an API to form a co-crystal is dependent on a 
range of variables, including the types of co-former, the API co-former ratio, the solvents, 
the temperature, the pressure, the crystallization technique, etc. Common functional groups, 
such as carboxylic or amino acids, amides, alcohols and carbohydrates are typically found to 
interact with one another in co-crystals (see Fig. 5) (Miroshnyk et al., 2009, Sarma et al., 2011; 
Qiao et al., 2011). Etter has studied hydrogen bonds in co-crystals and uses them as design 
elements. The hydrogen bond general rules are the following: (i) all good proton donors and 
acceptors are used in hydrogen bonding, (ii) if six-membered ring intramolecular hydrogen 
bonds can form, they will usually do so in preference to forming intermolecular hydrogen 
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bonds, and (iii) the best proton donors and acceptors remaining after intramolecular 
hydrogen-bond formation form intermolecular hydrogen bonds with one another. In 
addition, the selectivity of hydrogen bonding in co-crystals was demonstrated by using 
pyridines (Etter, 1991; Sarma et al., 2011). 
Based on the above mentioned facts co-crystal prediction includes the following steps: 
(i) determining whether a given set of two or more molecular components will undergo co-
crystallization; (ii) identifying the primary intermolecular interactions, e.g., hydrogen-bond 
motifs that will exist within a particular co-crystal structure; and (iii) envisioning the overall 
packing arrangement in the resulting co-crystal structure (Trask, 2007). 
Design and preparation of pharmaceutical co-crystals is a multi-stage process that can be 
schematically described in the following steps: (i) selection and research of APIs; 
(ii) selection of co-crystal formers; (iii) empirical and theoretical guidance; (iv) co-crystal 
screening; (v) co-crystal characterisation; (vi) co-crystal performance (Miroshnyk et al., 2009; 
Qiao et al., 2011). 
 
Figure 5. Possible formation of hydrogen bonds between synthons used in crystal engineering: acid-
acid (a), acid-amine (b), acid-amide (c), acid-imide (d), amide-amide (e), and alcohol-ether (f). 
3.3. Synthesis of co-crystals 
A pharmaceutical co-crystal is a single-crystalline solid that incorporates two neutral 
molecules, one being an API and the other a co-crystal former (Vishweshwar et al., 2006). 
Co-crystal former may be an excipient or another drug (Rodríguez-Hornedo et al., 2007). 
Pharmaceutical co-crystal technology is used to identify and develop new proprietary forms 
of widely prescribed drugs and offers a chance to increase the number of forms of an API. 
Crystalline forms can be generated by means of kinetically or thermodynamically controlled 
crystallization processes. Synthesis/processing of co-crystals can be accomplished via a 
number of methods, including slow solvent evaporation crystallization from solution, 
solvent-reduced (e.g. slurrying, solvent-drop grinding) and solvent-free (e.g. grinding, 
melt), high throughput crystallization and co-sublimation techniques (Shekunov & York, 
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2000; Morissette et al., 2004; Trask & Jones, 2005; Trask et al., 2005a; Trask et al., 2005b; Trask 
et al., 2006; Stahly, 2007; Berry et al., 2008; Takata et al., 2008; Friščić & Jones, 2009; 
Schultheiss & Newman, 2009; Qiao et al., 2011). Typically co-crystals are prepared by slow 
solvent evaporation that is only viable if compatible solubility in a given solvent exists 
between the components comprising the potential co-crystal. The potential benefits, 
disadvantages and methods of preparation of co-crystals were reported (Blagden et al., 
2007). Solvent drop grinding has been reported to be a cost-effective, green, and reliable 
method for discovery of new co-crystals as well as for preparation of existing co-crystals. A 
slurry crystallization technique was used in co-crystal screening of two non-ionizable 
pharmaceutical host compounds, stanolone and mestanolone, with 11 pharmaceutically 
acceptable guest acids, and the results demonstrated the importance not only of hydrogen 
bonding but also of geometric fit in co-crystal formation (Takata et al., 2008). In addition to 
these classical techniques of co-crystal synthesis, also more sophisticated methods can be 
mentioned such as electrochemical crystallization, gel crystallization, vapour-diffusion 
crystallization, cryogenic grinding (cryomilling), microporous membranes crystallization, 
supercritical fluids crystallization and sonocrystallization (Dahlin et al., 2011; Hsu et al., 
2002; Forsythe et al., 2002; He & Lavernia, 2001; Di Profio et al., 2007; Tong et al., 2001; 
Ruecroft et al., 2005). The combinations and variations of the above techniques may be used 
to cause co-crystal formation (McMahon et al., 2007). It is evident that many of the reported 
co-crystals appear to be the result of serendipity, although several groups have successfully 
exploited crystal engineering principles for design and synthesis of co-crystals. 
4. Characterization of co-crystals 
Co-crystal characterisation is an important constituent part of co-crystal research. The basic 
techniques of analysis of co-crystals involve especially solid state analysis methods 
(Zakrzewski & Zakrzewski, 2006; Dohnal et al., 2010), i.e. vibration-rotation spectroscopy, 
solid state NMR, thermal analysis, microscopy techniques and X-ray diffraction. The most 
often used solid-state analytical techniques will be discussed below. 
4.1. Spectroscopy of vibration-rotation transitions 
According to the used part of infrared (IR) spectra (energy), near infrared spectroscopy 
(NIR), middle infrared spectroscopy (MIR), Raman scattering and terahertz (THz) 
spectroscopy are distinguished. 
4.1.1. NIR Spectroscopy 
Photons in NIR region have the highest energy and can therefore vibrationally excite 
molecules into even higher excited vibrational states than the first level, i.e. the second, the 
third and others. These transitions are called overtons. Absorption of radiation in the NIR 
region is usually based on higher energy transitions between vibrational levels of molecules, 
namely combination transitions and overtones and not fundamental transitions, which are 
dominant in mid infrared region (MIR). NIR spectrometers are not so demanding of applied 
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materials, as are the instruments working in the mid infrared region, due to different 
radiation frequencies used in the NIR spectrometry. Acquisition of NIR spectra requires 
several seconds and can be performed during manufacturing process. Therefore, the NIR 
spectroscopy is still more often applied as a tool of process analytical technology. In 
co-crystal analysis NIR spectroscopy is commonly used as a screening method of the first 
choice (Pekárek & Jampílek, 2010). 
4.1.2. MIR spectroscopy and Raman scattering 
The aim is not only to present the basic principles of both methods, but also to compare them. 
Raman spectroscopy and mid-infrared spectroscopy are both widely used in the 
pharmaceutical industry for the solid-state characterization because of their specificity. MIR 
region is the most important region in terms of analytical application. It is a region, where the 
majority of the so-called fundamental vibrations appear, i.e. the vibrational transitions from 
the basic to the first excited vibrational state. Vibrational spectroscopy provides key 
information about the structure of molecules. Positions and intensities of bands in a 
vibrational spectrum can be used to determine the structure of a molecule or to determine the 
chemical identity of a sample. With sufficient experience it is possible to identify chemical 
compounds or monitor intermolecular interactions by evaluating changes in positions and 
intensities of Raman bands which is extremely useful for the above mentioned purposes. 
The mid-infrared and Raman spectra (with the exception of optical isomers) of a drug 
substance or any chemical compound are unique. Raman spectroscopy is a vibrational 
spectroscopy method which complements mainly the mid-IR spectroscopy. The intensity of 
bands in IR spectra is proportional to the dipole moment change occurring during the given 
type of the vibrational motion. Modes with a large change in the dipole moment having 
intensive bands in the IR spectra generally provide low-intensity bands in Raman spectra. 
Conversely, vibrations of non-polar functional groups provide intense bands in Raman 
spectra and weak bands in infrared spectra. (Zakrzewski & Zakrzewski, 2006; Pekárek & 
Jampílek, 2010). An important advantage of Raman spectroscopy over IR spectroscopy is the 
possibility to measure aqueous solutions. This advantage can be used in identification of 
APIs in aqueous solutions, emulsions or suspensions. 
4.1.3. THz spectroscopy 
This technique covers a wide interval, which can be roughly defined, for example, by 
frequencies of 100 GHz and 3 THz, which corresponds to wavelengths between 3 and 
0.1 mm, i.e. wave numbers from 3 to 100 cm-1. Hence THz region partially overlaps with 
far-infrared region. The characteristic frequency of 1 THz can be equivalently expressed in 
other spectroscopic units. The decisive factor for expansion of this method was the 
development of optical femtosecond lasers being an integral part of the most current 
laboratory and commercial THz spectrometers. Attractiveness of the THz field lies in the 
scale of the specific options for application of electromagnetic radiation of these frequencies. 
Application options in pharmaceutical analysis are mainly spectroscopy and imaging. 
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Solid substances often exhibit specific interactions in the THz region. While some crystals 
are transparent in this range, many others show low-frequency oscillations of the crystal 
structure (called phonon bands) with characteristic frequencies being determined by short-
range inter-atom interactions and even arrangement of atoms at long distances (Kadlec & 
Kadlec, 2012). Similar to NIR and mid-IR spectroscopy, in THz spectroscopy reflectance (less 
often) and transmittance measurements are used. 
It is known that vibrational modes of amorphous and crystalline substances are very 
different. This was experimentally proven, for example, in THz spectra of samples of 
crystalline and amorphous saccharides (Walther et al., 2003). The absence of sharp 
vibrational modes that can be observed in the crystalline form was later also confirmed in 
THz spectra of indomethacin (Strachan et al., 2004). 
Determination of tablet coating thickness and determination of particle size belong among 
special applications of THz spectroscopy. Radiation in THz region has the lowest energy, 
which can cause changes mainly in rotational energy of molecules therefore it has the lowest 
(destructive) influence on measured co-crystals. 
4.2. Solid state nuclear magnetic resonance 
Solid state NMR (ssNMR) spectroscopy is not used for routine analyses in pharmacy 
because of its demands, but its role in pharmaceutical development is indispensable. It has 
very wide application. The most important applications can be divided into the following 
groups (Havlíček, 2010): (i) API structural analysis; (ii) polymorphism; (iii) co-crystal 
analysis; (iv) dosage form analysis; (v) solvate analysis; (vi) salt analysis. 
Among the most widely used ssNMR techniques CP/MAS NMR belongs. It has three 
modifications: cross polarization (CP), magic angle spinning (MAS) and high-power 
heteronuclear decoupling. With this arrangement the sensitivity and line broadening 
problems were overcome, and high-resolution ssNMR was brought in practical use. 
Solid-state NMR is capable of providing detailed structural information about organic and 
pharmaceutical co-crystals and complexes. ssNMR non-destructively analyzes small 
amounts of powdered material and generally yields data with higher information content 
than vibrational spectroscopy and powder X-ray diffraction methods. Particularly, its ability 
to prove or disprove molecular association and possibility to observe structural features 
(such as hydrogen bonding) are great advantages of this method. These advantages can be 
utilized in the analysis of pharmaceutical co-crystals, which are often initially produced 
using solvent drop grinding techniques that do not lend themselves to single-crystal growth 
for X-ray diffraction studies (Vogt et al., 2009). 
4.3. Thermal analysis 
Thermal analysis is a broad term referring to methods (see Table 1), which measure physical 
and chemical properties of a substance, a mixture of substances or also of a reaction mixture 
as a function of temperature or time during a controlled temperature programme. Most of 
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these methods monitor corresponding system properties (mass, energy, size, conductivity, 
etc.) as dynamic functions of temperature. 
For co-crystal analysis mainly differential scanning calorimetry (DSC) and its modifications, 
differential thermal analysis (DTA) and thermogravimetry analysis (TGA), are of great 
importance. For special cases a very useful method is thermally stimulated current (TSC). 
DSC and DTA are the most applied methods of thermal analysis in pharmaceutical 
development. In DSC, the sample is subjected to linear (or modulated) heating, and the heat 
flow rate in the sample is proportional to the actual specific heat and is continuously 
measured. Very interesting and useful modifications of DSC are hyperDSC, microDSC and 
modulated DSC (Krumbholcová & Dohnal, 2010). 
 
Method name Tracked value
Differential thermal analysis 
(DTA) 
temperature difference between the studied and the 
standard sample 
Differential scanning calorimetry
 (DSC) 
thermal energy provided for compensation of 
temperature between the studied and the standard 
sample 
Thermogravimetry analysis 
(TGA) 
weight change 
Thermomechanical analysis 
(TMA) 
change in a mechanical property (module, hardness) 
Dilatometry change in volume 
Effluent gas analysis volume of the studied gas 
Pyrolysis pyrolysis products 
Thermal luminescence analysis emission of light 
Electric conductivity analysis change in electric conductivity 
Table 1. List of the most common methods of thermal analysis. (Ref. Krumbholcová & Dohnal, 2010). 
4.3.1. Thermally stimulated current 
This special thermal method uses a so-called molecular mobility, which provides 
information about the structure of substances, about dynamic parameters H and S and 
the relaxation (release) time . In TSC the substance is heated to a temperature TP in an 
electric field with intensity EP for a period of time tP, which is sufficient for differently 
moving particles of the studied substance to reach identical orientation in the electric field. 
In this state, the sample is rapidly cooled to a temperature T0, which ensures zero motion of 
the particles. The effect of the electric field is then also deactivated, and the substance is then 
kept at temperature T0 for time t0. The temperature then linearly increases, and the substance 
returns to the previous balance, and depolarization current ID is recorded as a function of 
temperature. Each depolarization peak is characterized by temperature Tmax with intensity 
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Imax. This technique is particularly suitable for substances with polar character. It can 
distinguish polymorphs or co-crystals, which cannot be determined by classical DSC 
(Krumbholcová & Dohnal, 2010). 
4.4. X-Ray diffraction 
X-Ray diffraction is one of the basic solid state analytical techniques labelled as the "gold 
standard". It is used not only for characterization and identification of crystalline substances 
but also for their discrimination. 
Two basic methods are discerned according to the type of the analysed sample. They are: 
1. Diffraction on single crystal (single-crystal X-ray diffraction, SCXRD), 
2. Powder diffraction (X-ray powder diffraction, XRPD). 
 
Name single-crystal X-ray diffraction X-ray powder diffraction 
Abbreviation SCXRD XRPD 
Sample – type Single crystal Powder 
Sample – amount 1 single crystal with size of 0.1 – 1 mm 100 – 500 mg 
Sample – 
preparation 
Selection of a suitable single crystal and 
its fixation onto the goniometric head. 
Filling of the holder cavity 
or possibly milling. 
Sample – 
consumption 
Non-destructive Non-destructive 
Measurement 
time 
Hours/days Minutes/hours 
Analysis of 
obtained data 
Complete information about the 
molecule, conformation, bond lengths, 
chirality, spatial arrangement of 
molecules in the crystal, interactions 
between molecules, determination and 
location of solvents. 
„Fingerprint" of the crystal 
structure 
Principle of the 
method 
Monochromatic light falls on a single 
crystal, and because only one lattice 
diffracts, it is necessary to rotate the 
crystal to obtain the desired set of 
reflections (the principle of four-circle 
diffractometer). 
Monochromatic radiation 
impacts a polycrystalline 
material and all lattices that 
meet the diffraction 
condition diffract at the 
same time. 
Practical 
application 
Crystallographic studies: determination 
of the complete structure of an API, a 
protein, a complex, etc. 
Mainly industrial, screening 
and control method for 
characterization of 
crystalline materials. 
Table 2. Comparison of basic diffraction methods. (Ref. Brusová, 2010). 
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Their basic characteristics, advantages and disadvantages are summarized in Table 2. The 
X-ray structural analysis methods, which use single-crystal samples, often allow a complete 
determination of crystallographic characteristics. Diffraction on a single-crystal yields 
intensities of diffractions on individual configurations of the crystallography planes, 
individually for each of their orientation, and the number of the detected maxima is very 
high, in orders of 102 – 104. In the powder diffraction, on a debyeogram or a diffractogram 
there at most 100 lines can be distinguished. In addition, each diffraction line is a 
superposition of diffractions of all inequivalent and equivalent planes (Hušák et al., 2007; 
Kratochvíl et al., 2008). 
5. Carbohydrates and their derivatives as crystallization modifiers 
As discussed above, pharmaceutical co-crystals have rapidly emerged as a new class of API 
solids demonstrating great promise and numerous advantages. Various co-crystals of APIs 
were prepared by reason of intellectual property protection, for example, imatimib (see Fig. 6, 
structure I) with co-crystal carbohydrate formers such as α-D-glucopyranose, 
D-fructofuranose and N-methyl-D-glucamine (meglumine) (Král et al., 2010); agomelatine (see 
Fig. 6, structure II) with carbohydrate counterions such as D-sorbitol, aspartame, phenyl-β-D-
glucopyranoside, D-glucoheptono-1,4-lactone, D-(+)-trehalose, lactose, α-D-glucopyranose, 
saccharose, N-methyl-D-glucamine and D-(+)-glucosamine hydrochloride (Ferencova et al., 
2012); or to improve permeability, for example, alendronate (see Fig. 6, structure III), 
ibandronate (see Fig. 6, structure IV) or risedronate (see Fig. 6, structure V) with a number of 
carbohydrates as co-crystal formers (Jampílek et al., 2009; Haroková, 2010; Havelková, 2010; 
Hrušková, 2010; Jampílek et al., 2010; Kos, 2010; Oktábec et. al, 2010; Kos et al., 2011; Ťažká 
2011; Havelková, 2012; Oktábec, 2012). 
 
Figure 6. APIs used as host of carbohydrate formers. 
The present study deals with the design and an effort to prepare co-crystals/new entities, 
generally new solid phases, of the above discussed bisphosphonates III-V. These 
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compounds were investigated in detail, and a lot of valuable knowledge concerning 
generation of solids was obtained. Bisphosphonates (BPs) can be denoted as top-selling 
APIs. BPs are the most widely used and the most effective bone resorption inhibitors 
currently available for treatment of Paget’s disease, tumour-associated bone disease and 
osteoporosis. All BPs have high affinity for bone mineral as a consequence of their P-C-P 
backbone structure, which allows chelation of calcium ions (Ebetino et al., 1998). Following 
release from bone mineral during acidification by osteoclasts, BPs appear to be internalized 
specifically by osteoclasts, but not other bone cells. The intracellular accumulation of BP 
leads to inhibition of osteoclast function due to changes in the cytoskeleton, loss of the 
ruffled border (Carano et al., 1990; Sato et al., 1991) and apoptosis (Hughes et al., 1995; 
Selander et al., 1996; Ito et al., 1999; Reszka et al., 1999). The ability of BPs to inhibit bone 
resorption depends on the presence of two phosphonate groups in the P-C-P structure, 
which appears to be required for interaction with a molecular target in the osteoclast as well 
as for binding bone mineral (Rogers et al., 1995; van Beek et al., 1998; Rogers et al., 2000). 
BPs as pyrophosphate analogues are a group of drugs that are widely used in practice. 
There are several injectable bisphosphonates: etidronate, pamidronate and zoledronate, 
which may be administered every three months or yearly. Peroral BPs alendronate and 
risedronate are taken daily, weekly or monthly, and ibandronate is approved to be taken 
monthly. Oral bioavailability of these BPs is very low (their gastrointestinal absorption is 
about 1%) due to their high hydrophilicity (Ezra & Golomb 2000). 
A number of various patented solid forms of each API from this group can be found, which, 
for example, complicates their utilization for generic formulation from the intellectual 
property point of view. Eiermann et al. prepared crystalline forms of ibandronate (IV) B and 
A (Eiermann et al., 2006a; Eiermann et al., 2006b). Lifshitz-Liron et al. obtained forms C, D, 
E, F, G, H, J, K, K2, K3, Q, Q1, Q2, Q3, Q4, Q5, Q6, QQ, R, S and T (Lifshitz-Liron et al., 
2006). Muddasani et al. prepared polymorphs I and II (Muddasani et al., 2007), and 
Devaraconda et al. generated ibandronate forms III-XXXI (Devarakonda et al., 2010). Ten 
different polymorphic and pseudo-polymorphic forms of sodium risedronate (V) identified 
as A, B, B1, BB, D, E, F, G and H and a semi-crystalline form were described (Cazer et al., 
2001; Aronhime et al., 2003a; Aronhime et al., 2003b; Richter et al., 2007). The crystal 
structures of four different hydrates (monohydrate, dihydrate, hemipentahydrate and 
variable hydrate) and an anhydrate of sodium risedronate (V) have been elucidated and 
discussed by Redman-Furey (Redman-Furey et al., 2005) and Gossman (Gossman et al., 
2003). Recently three new phases were found and named J, K and M (Bruning et al., 2011). 
This paper deals with investigation of various types of carbohydrates and their derivatives 
as crystallization modifiers applied to crystal study concerning the BP family. 
Carbohydrates were used due to their hydroxyl moieties, which are able to interact with a 
phosphoric group and/or a nitrogen atom in the alkyl chain or heterocycle. Carbohydrates 
also provided a unique excellent system of hydroxyl moieties in different stereochemical 
modifications. These hydroxyl groups can be straightly modified, for example, by 
alkylation/arylation, and the structure of the carbohydrate molecule obtains absolutely 
different three-dimensional/space properties. 
 
Investigation of Carbohydrates and Their Derivatives as Crystallization Modifiers 99 
 
 
Figure 7. Structures of sugar alcohols used as potential co-crystal/crystallization formers. 
 
Figure 8. Structures of furanoses used as potential co-crystal/crystallization formers. 
 
Figure 9. Structures of hexoses used as potential co-crystal/crystallization formers. 
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Thus mixtures of BPs with various sugar alcohols, furanoses, pyranoses and gluco-, manno- 
and galactopyranoside derivatives, some amino carbohydrates and disaccharides (see Figs. 
7-11) as counterions were designed in an effort to prepare new crystalline forms or co-
crystals/new entities. Mixtures of BPs and carbohydrates in different ratios and under 
various conditions were prepared. All the prepared mixtures (solid compounds) were 
characterized using some of the above mentioned solid state analytical techniques 
(Haroková, 2010; Havelková, 2010; Hrušková, 2010; Kos, 2010; Oktábec et. al, 2010; Kos et 
al., 2011; Ťažká 2011; Havelková, 2012; Oktábec, 2012). 
 
Figure 10. Structures of pyranosides used as potential co-crystal/crystallization formers. 
5.1. Generation of samples 
All the evaluated samples with ratios 1:1 (A), 1:2 (B) and 1:3 (C) were prepared by means of 
dissolution of bisphosphonate monosodium salt and the excipient in water, subsequently 
mixed (1 h) and slowly evaporated at ambient temperature. To some samples with ratios 1:2 
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and 1:3 methanol was slowly added dropwise as an anti-solvent. The solid precipitated 
compound was filtered and dried at ambient temperature, samples 1:2 (D) and 1:3 (E), and 
the remaining liquid part was slowly evaporated at ambient temperature, samples 1:2 (F) 
and 1:3 (G). All generated solid compounds were subsequently screened by means of 
FT-NIR and FT-Raman spectroscopy. If a sample differing from the starting materials was 
found, it was additionally characterized by the below mentioned methods (Jampílek et al., 
2009; Haroková, 2010; Havelková, 2010; Hrušková, 2010; Jampílek et al., 2010; Kos, 2010; 
Oktábec et. al, 2010; Kos et al., 2011; Ťažká 2011; Havelková, 2012; Oktábec, 2012). 
 
Figure 11. Structures of disaccharides used as potential co-crystal/crystallization formers. 
5.2. Used solid-state analytical techniques 
Near infrared spectra were recorded using a Smart Near-IR UpDrift™, Nicolet™ 6700 FT-IR 
Spectrometer (Thermo Scientific, USA). The spectra were obtained by accumulation of 
128 scans with 4 cm–1 resolution in the region of 12800–4000 cm-1. FT-Raman spectra were 
accumulated by an FT-Raman spectrometer RFS 100/S (Karlsruhe, Bruker, Germany). The 
spectra were obtained by accumulation of 256 scans with 4 cm-1 resolution in the back 
scattering geometry with the laser wavelength of 1064 nm. 31P CP/MAS NMR Spectra were 
recorded on a Bruker AVANCE 500 MHz spectrometer (Karlsruhe, Bruker, Germany). The 
31P CP/MAS spectra were measured in 4 mm rotor at 10 kHz with 2 ms contact time. 
31P chemical shift of NH4H2PO4 (0 ppm) was used as an external reference for 31P chemical 
shift. The 13C CP/MAS spectra were measured in 4 mm rotor at 13 kHz with 2 ms contact 
time. Carbon chemical shifts were referenced to the signal for TMS via a replacement sample 
of glycine (176 ppm for the carbonyl group signal). The XRPD patterns were obtained on a 
PANalytical X’PERT PRO MPD diffractometer with Cu Kα radiation (45 kV, 40 mA). The 
powder samples were measured on Silica plate holder. Data were recorded in the range 
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2-40° 2θ, with 0.01° 2θ step size and 50 s/step scan speed. For the measurement of 
differential scanning calorimetry (DSC) curve an instrument DSC Pyris 1 (PerkinElmer, 
USA) was used. Maximum sample weight was 3.5 mg, and the standard Al sample pan was 
used. The record of the DSC curve was in the range of 50–300 °C at the rate of 10.0 °C/min 
under a nitrogen atmosphere. 
5.3. Crystal products of carbohydrates with alendronate and ibandronate 
Although a number of carbohydrates were tested as potential co-crystal/crystallization 
formers, no change in the crystal structure of the used alendronate sodium salt (III) was 
obtained. The starting material was always obtained. 
Mixtures of ibandronate monosodium salt (IV) with twenty-eight carbohydrates were 
generated by means of thermodynamically and/or kinetically controlled crystallization 
processes. Polymorph B of ibandronate monosodium salt monohydrate (sodium hydrogen 
{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonate, IV) was used as a 
starting material (Eiermann, 2006a), which is the most common in pharmaceutical 
formulations. It is a white powder, freely soluble in water and practically insoluble in 
organic solvents. 
From all the tested agents, only phenyl-β-D-galactopyranoside (see Fig. 10, structure 24) 
yielded noteworthy products with BP IV. The rest of the tested carbohydrates, except phenyl-
β-D-glucopyranoside (see Fig. 10, structure 21) and 2-naphthyl-β-D-galactopyranoside (see 
Fig. 10, structure 25), generated again the starting polymorph B. The mentioned two 
carbohydrates 21 and 25 provided mixtures of polymorphs A+B, as shown in Table 3. 
Samples of IV-24 in ratios 1:1 (A), 1:2 (B) and 1:3 (C) were prepared by mixing and 
subsequent evaporation at ambient temperature. In all three samples a change in the NIR 
spectra can be observed in the range of 5,300-4,800 cm-1. The spectra of samples IV-24/B and 
IV-24/C are very similar, only slightly different from sample IV-24/A, probably due to the 
lower crystallinity of sample IV-24/A, which causes broader bands in the spectrum. As 
samples IV-24/A-C were prepared in the same way, it can be concluded that increasing 
concentration of compound 24 influences the sample crystallinity. 
 
Comp. A B C D E F G 
IV-21 B B B B B A+B A+B 
IV-24 new new new B B new new 
IV-25 B B B B B A+B A+B 
Table 3. Samples of ibandronate (IV) and used carbohydrates 21, 24 and 25 in ratios 1:1, 1:2 and 1:3 
prepared by evaporation at ambient temperature (A, B, C), samples in ratios 1:2 and 1:3 prepared by 
methanol precipitation (D, E) and samples in ratios 1:2 and 1:3 prepared by addition of methanol and 
evaporation of liquid part at ambient temperature (F, G). (Ref. Oktábec et al., 2010; Havelková, 2012). 
Based on the NIR spectra of samples of IV-24/D and IV-24/E in ratios 1:2 and 1:3 
precipitated by methanol and filtered, it can be concluded that both samples contain only 
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form B of compound IV. The same characteristic bands in the range of 5,300-4,800 cm-1 as for 
samples IV-24/A-C can be observed for samples IV-24/F and IV-24/G in ratios 1:2 and 1:3 
after addition of methanol, filtration of the obtained precipitate and evaporation at ambient 
temperature. Based on this fact it can be concluded that addition of methanol does not 
influence generation of a new unknown solid phase, because the same products were 
yielded with and without methanol addition. Slow evaporation seems to be important, i.e. 
thermodynamically controlled crystal modification is probable. The presence of 
carbohydrate 24 is fundamental for generation of a new entity. The samples IV-24/A-C and 
IV-24/F, IV-24/G were also characterized by means of the FT-Raman spectrometry and 
31P CP/MAS NMR spectroscopy for verification of this hypothesis. Both methods confirmed 
the presence of new solid phases. 
From the above mentioned results (Table 3) it is evident that ibandronate (IV) provided a 
new solid phase only with phenyl-β-D-galactopyranoside (24). These samples, IV-24/A-C 
and IV-24/F, IV-24/G, were generated under the thermodynamic conditions (slow 
evaporation at ambient temperature) without or with methanol. It can be concluded that the 
presence of the co-crystal/crystallization former and the thermodynamic conditions were 
essential for generation of the new solid phase. Note that only β-D-pyranosides with 
substituted hydroxyl moiety in C(1), position 2 of the tetrahydropyran ring, e.i. in the 
equatorial position, showed interactions with BP IV. Although phenyl-α-D-pyranosides 
were not evaluated, it is possible to suppose that α-D-pyranosides possess probably a 
disadvantageous configuration of C(1) hydroxyl moiety. 
Based on the above discussed results it can be also stated that substitution of C(1) hydroxyl 
with the aromatic group is necessary for interactions, because e.g. methyl-β-D-
galactopyranoside (23) contrary to phenyl- (24) or naphthyl-β-D-galactopyranoside (25) 
provided no modification of the starting polymorph of compound IV. This hypothesis is 
supported by the fact that phenyl-β-D-glucopyranoside (21) afforded also the change of 
polymorph B to form A of BP IV. It can be assumed that naphthyl is too bulky compared to 
the phenyl ring. Nevertheless from all the evaluated substituted pyranosides only phenyl-β-
D-galactopyranoside (24) yielded the new solid phase of compound IV. As non-covalent 
interactions are important for generation of crystal forms, the space configuration of all the 
hydroxyl moieties is probably essential for interactions between BP IV and carbohydrate 24. 
As illustrated in Fig. 10, where basic spatial configuration of substituted pyranosides is 
shown, different interactions between phenyl-β-D-galactopyranoside (24) and phenyl-β-D-
glucopyranoside (21) are probably caused by opposite orientation of hydroxyl moiety in C(4) 
in position 5 of the tetrahydropyran ring. In compound 21 this hydroxyl moiety is 
trans-oriented (in equatorial configuration) to the hydroxymethyl group in C(5) in position 6 
of the tetrahydropyran ring, while in compound 24 it is cis-oriented (in axial configuration), 
which at the same time guarantees space proximity to the pyran oxygen. Pyranoside 24 
possesses cis-orientation of hydroxyl moieties in C(3) and C(4) in positions 4 and 5 of the 
tetrahydropyran ring together with the phenoxy moiety in C(1) in position 2 of the 
tetrahydropyran ring. This fact together with cis-orientation of the hydroxymethyl group in 
C(5) in position 6 probably results in essential three-point interaction of neighbouring 
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hydroxyl moieties between compound 24 and BP IV that is completed by interactions of the 
adjacent phenoxy moiety and pyran oxygen in comparison with carbohydrate 21, see Fig. 
10. 
5.4. Crystal products of carbohydrates with risedronate 
The semi-crystalline risedronate monosodium salt sodium 1-hydroxy-1-phosphono-2-
(pyridin-3-yl-ethyl)phosphonate, (V) was used as a starting material (Richter et al., 2007). It 
is a white powder, freely soluble in water and practically insoluble in organic solvents. The 
sodium hemipentahydrate, which is the marketed form A, is the most stable of all these 
forms at ambient conditions (298 K, 50% room humidity) (Cazer et al., 2001). 
From all the tested agents only phenyl-β-D-galactopyranoside (24) with risedronate (V) 
yielded noteworthy products. Other tested carbohydrates yielded either risedronate form A 
(in most cases), form H (in the case of the samples with myo-inositol (see Fig. 7, structure 4), 
D-lyxofuranose (see Fig. 8, structure 9), phenyl-β-D-glucopyranoside (21) and naphthyl-β-D-
galactopyranoside (25) prepared by addition of methanol and evaporation of the liquid part 
at ambient temperature) or impure form B in the case of the sample with β-D-allopyranose 
(see Fig. 9, structure 13) precipitated by methanol. A rapid change in solubility equilibrium 
and fast precipitation (kinetically controlled crystallization process) caused generation of 
different form B (samples V-13/D and V-13/E), while slow evaporation, i.e. 
thermodynamically controlled crystallization, led to preparation of stable polymorphs A or 
H. β-D-Allopyranose (13) modifies the environment from which compound V was 
crystallized, but this carbohydrate was not detectable in the final crystalline form. Based on 
this fact it can be concluded that the addition of methanol as an anti-solvent is crucial for 
generation of this different/uncommon solid form. 
Different interactions of BP V with carbohydrate 13 are probably caused by the opposite 
orientation of hydroxyl moieties in C(1) and C(3) in positions 2 and 4 of the tetrahydropyran 
ring in comparison with α-D-gluco-, α-D-manno- and α-D-galactopyranose (10-12). The 
β-position of the hydroxyl moiety in C(1) of β-D-allopyranose (13) possesses also 
cis-orientation (axial configuration, see Fig. 9) with respect to the pyran oxygen in position 1 
of the tetrahydropyran ring. As bonds influencing generation of crystalline forms are 
formed by non-binding interactions (e.g. by H-bonds, ionic bonds, van der Waals forces 
(dispersion attractions, dipole-dipole, dipole-induced dipole interactions) and hydrophobic 
interactions), the steric arrangement of hydroxyl moieties on pyranose skeletons is 
important for formation of interactions, as discussed above. 
Samples of V-24/A-C were prepared by mixing saturated aqueous solutions and subsequent 
evaporation of water at ambient temperature. All three samples contained polymorph A of 
risedronate (V) (the most thermodynamically stable form). Samples V-24/D and V-24/E 
precipitated by methanol and filtered yielded again polymorph A of compound V. Samples 
V-24/F and V-24/G were generated by addition of methanol and filtration of the obtained 
precipitate with following evaporation at ambient temperature. Samples V-24/F and V-24/G 
were absolutely different from all the above mentioned samples. A change in the NIR 
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spectra of samples V-24/F and V-24/G was observed in the range of 7,100–4,900 cm−1. Both 
samples were also characterized by means of FT-Raman spectrometry and 31P and 13C 
CP/MAS NMR spectroscopy for verification of the above mentioned hypothesis. Sample V-
24/G was a mixture of polymorph A and the amorphous form of V, but sample V-24/F was 
confirmed as a new crystalline form of BP V. Therefore solid V-24/F was additionally 
characterized by means of XRPD (Fig. 12) and also by DSC. A XRPD pattern corresponds to 
a crystalline sample. Visual comparison of the measured pattern with those published 
previously (Aronhime et al., 2003; Bruning et al., 2011) revealed that a new solid phase of BP 
V was formed. It is also supported by the absence of peaks of co-crystal former 24. It can be 
concluded that the presence of compound 24 and slow evaporation, i.e. thermodynamically 
controlled crystallization process, with a small amount of methanol as anti-solvent provided 
risedronate (V) in an unknown form that was named as polymorph P. 
Sugar alcohols did not provide any different forms or co-crystals with risedronate (V). The 
polyols used are acyclic compounds, or probably important heterocyclic oxygen is not 
present in the ring. In the case of myo-inositol (4), where only the different polymorph H of 
compound V was detected, cis-oriented hydroxyl moieties are in C(1), C(2), C(3) and C(5) or 
conversely oriented hydroxyl moieties are in C(4) and C(6), see Fig. 7. Contrary to the rest of 
the tested unsubstituted carbohydrates, only β-D-allopyranose (13) shows cis-orientation of 
hydroxyl moieties in C(1) and C(5/6) in positions 2 and 6 of the tetrahydropyran ring together 
with the pyran oxygen in position 1 and cis-orientation of hydroxyl moieties in C(2), C(3) and 
C(4) in positions 3, 4 and 5 of the tetrahydropyran ring, i.e. cis-orientation of three sequential 
hydroxyl moieties. These facts are probably essential for interactions between BP V and 
carbohydrate 13. For example, α-D-galactopyranose (12) possesses 1, 4, 5, 6 cis-oriented 
pyran oxygen together with hydroxyl moieties; α-D-glucopyranose (10) possesses 1, 4, 6 
cis-oriented pyran oxygen together with hydroxyl moiety; and α-D-mannopyranose (11) 
possesses 3, 4, 6 cis-oriented hydroxyl moieties together with pyran oxygen in position 1. 
 
Figure 12. XRPD patterns of new solid phase V-24/F named as polymorph P. 
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According to the above mentioned hypothesis, interactions with BP V should be predicted only 
for D-lyxofuranose (Fig. 8, structure 9) from the furanose family. D-Lyxofuranose (9) shows cis-
orientation of hydroxyl moieties in C(2) and C(3) in positions 3 and 4 of the tetrahydrofuran ring 
together with the furan oxygen in position 1. Nevertheless, this three-point interaction of 
carbohydrate 9 with BP V, which however is not completed by other additional/secondary 
interactions, is not sufficient for generation of a different form or co-crystal of BP V, when only 
form H was generated using compound 9. Probably the conformation of the tetrahydrofuran 
ring different from the pyranose chair conformation is also important. 
Different interactions of risedronate monosodium salt (V) with phenyl-β-D-galactopyranoside 
(24) compared to other evaluated O-substituted pyranosides are probably caused by the 
opposite orientation of the hydroxyl moiety in C(4) in position 5 of the tetrahydropyran ring, as 
it is shown in Fig. 10 and discussed in Section 5.3. β-Position of the hydroxyl moiety in C(1) of 
β-D-gluco- and β-D-galactopyranoside (as well as in β-D-allopyranose) possessing also cis-
orientation to the pyran oxygen together with phenyl substitution of this hydroxyl moiety 
seems also to be an important assumption for interactions. For example, methyl-β-D-
galactopyranoside (23) did not show any interactions with compound V, whereas phenyl-β-D-
glucopyranoside (21) and naphtyl-β-D-galactopyranoside (25) generated polymorph H of 
compound V, and phenyl-β-D-galactopyranoside (24) provided a new solid phase. Aliphatic 
alkoxy moieties (methoxy, octyloxy) show absolutely different physico-chemical properties, i.e. 
non-binding interactions compared with the aromatic phenyl nucleus. On the other hand, a 
naphthyl moiety, which is comparable with a phenyl ring, does not meet steric requirements 
to generate a new solid phase with compound V. Contrary to the rest of the tested 
O-substituted pyranosides, carbohydrate 24 shows cis-orientation of hydroxyl moieties in C(3), 
C(4) and C(5-6) in positions 4, 5 and 6 of the tetrahydropyran ring, i.e. three sequential hydroxyl 
moieties that possess cis-orientation with the phenoxy moiety in C(1) in position 2 of the 
tetrahydropyran ring together with the pyran oxygen in position 1, as was mentioned in 
Section 5.3. This configuration of all the hydroxyl moieties, as illustrated in Fig. 10, is probably 
essential for interactions between risedronate (V) and phenyl-β-D-galactopyranoside (24). 
6. Future research 
Samples IV-24/A-B and IV-24/F, IV-24/G should be characterized by XRPD. Also some of 
the above mentioned samples as well as sample V-24/F (polymorph P) should be analyzed 
using single-crystal X-ray diffraction (SCXRD), i.e. monocrystals should be prepared for 
absolute characterization of their structure. Based on the above described primary screening, 
other carbohydrate derivatives should be synthesized, especially various substituted 
β-D-pyranosides, e.g. O-arylated or O-alkylated. For example, based on the screening of 
these carbohydrates, it was confirmed that the structure derived from β-D-galactopyranose 
could be a successful candidate for modification of a crystalline form of BPs. 
In the recent past, molecular modelling and/or molecular dynamics simulates started 
playing an increasingly important role in detection of molecule interactions. These 
computational techniques allow investigating possible binding modes of compounds. 
Therefore the priorities are advanced simulation of interactions between carbohydrate 
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derivatives and various APIs and modelling/computing of physico-chemical properties of 
these new potential solids by means of various advanced simulating software products and 
subsequent transfer of the results of this systematic virtual screening to practice. 
7. Conclusion 
Twenty-eight carbohydrate derivatives were evaluated as formers during crystallization 
process of monosodium salts of alendronate (III), ibandronate (IV) and risedronate (V). All 
prepared samples were screened by FT-NIR and FT-Raman spectroscopy, and some new 
entities were checked by 31P and 13C CP/MAS NMR spectroscopy, XRPD and DSC. In the 
present study the relationships between the chemical structures of bisphosphonates and 
carbohydrates required for crystalline form change are investigated and discussed. It can be 
concluded that in general carbohydrates can be used as crystallization modifiers, although none 
of carbohydrates afforded a new solid phase with alendronate (III). Ibandronate (IV) and 
risedronate (V) generated new solid phases with phenyl-β-D-galactopyranoside (24). It is worth 
to note that both BPs IV and V contain trisubstituted nitrogen in contrast to alendronate (III), 
which can be an important factor that can cause different interactions. In case of BP IV it can be 
speculated about co-crystal generation; in case of BP V the new crystal form, polymorph P, is 
explicitly characterized. In both cases thermodynamically controlled crystallization was 
successful. The fundamental steric requirements to carbohydrate formers for generation of a 
new solid phase is β-orientation of hydroxyl moiety in C(1) in position 2 of the tetrahydropyran 
ring together with cis-orientation of at least three vicinal hydroxyl moieties and the pyran 
oxygen. β-Hydroxyl moiety in C(1) have to be substituted by an aromatic or heteroaromatic ring. 
It is also important to note that all the used carbohydrates can chelate the sodium cation in 
monosodium salts of BPs, and thus the sodium cation can contribute to the binding of BPs and 
carbohydrate with convenient conformation. The sodium cation can make the complex 
energetically favourable and help to retain the proper topology of the binding phosphates of 
BPs and the proper orientation of the hydroxyl moieties of a carbohydrate. 
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